(TheNewswire)
LONDON, ONTARIO – TheNewswire - December 11,2020 – At the request of IIROC (“InvestmentIndustry Regulatory Organization of Canada”), Sernova Corp.(“Sernova” or the “Company”) (TSX-V:SVA) (OTCQB:SEOVF)(FSE:PSH) wishes to confirm that the Company’s management is unawareof any material or undisclosed information or change in theCompany’s operations that would account for the recent increase inprice and market activity.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutictechnologies using a medical device and immune protected therapeuticcells (i.e. human donor cells, corrected human cells, and stemcell-derived cells) to improve the treatment and quality of life ofpeople with chronic metabolic diseases such as insulin-dependentdiabetes, blood disorders including hemophilia, and other diseasestreated through replacement of proteins or hormones missing or inshort supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
Copyright (c) 2020 TheNewswire - All rights reserved.